-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Anterior temporal dementia (FTD) describes a group of clinically, genetically and pathologically heterogeneous diseases characterized by degeneration of the frontal and temporal cortex
.
About one-third of all FTDs are hereditary.
In recent years, some studies have used a series of neuroimaging techniques to determine presymptomatic changes in hereditary FTD, although most of them have focused on structure, function, or perfusion magnetic resonance imaging (MRI)
.
Positron emission tomography (PET) imaging research is more limited, mainly focusing on-fluorodeoxyglucose (FDG-PET), which is a measurement method of glucose metabolism in the body, and low metabolism is considered to reflect neuronal dysfunction
They recruited 18 asymptomatic P301L MAPT mutation members from 5 families, 6 mutation carriers and 12 mutation negative controls
.
All participants underwent standard behavioral and cognitive assessments, as well as [18F]FDG-PET and 3D T1-weighted MRI brain scans
The estimated average age (standard deviation) for the mutant gene carrier group from the onset of symptoms was 12.
5 (3.
Compared with the control group (1.
36[0.
09]), the [18F]FDG intake of the anterior cingulate gyrus of mutation carriers was significantly reduced (average 1.
25[standard deviation 0.
07])
.
Compared with the control group (0.
68%[0.
08%]), the anterior cingulate gray matter volume of mutation carriers also showed a similarly significant reduction (0.
60%[0.
06%])
.
No other group differences were seen in other regions
The important significance of this study lies in the discovery: in a group of P301L MAPT mutation carriers, both the lower anterior cingulate metabolism and atrophy are obvious pre-symptomatic manifestations
.
Such a specific marker may prove to help stratify asymptomatic mutation carriers in future trials
In a group of P301L MAPT mutation carriers, low anterior cingulate metabolism and atrophy are both obvious pre-symptomatic manifestations
Original source:
Clarke MTM, St-Onge F, Beauregard JM, et al.
Early anterior cingulate involvement is seen in presymptomatic MAPT P301L mutation carriers.
Leave a message here
